These results were confirmed with the novel OGT inhibitor OSMI-1, and combinatorial treatments with either rotenone or metformin statistically significantly decreased the viability and blocked proliferation of prostate cancer cells but had no effect on cells representing normal prostate tissue (Suppl. Here, OGT is linked to prostate cancer.